DexCom, Inc. vs Live Nation Entertainment, Inc. — how do they compare? DexCom, Inc. trades at $85.22 (market cap $31.86B), while Live Nation Entertainment, Inc. trades at $173.84 (market cap $39.92B). The key difference: Live Nation Entertainment, Inc. is the larger of the two by market cap, and DexCom, Inc. is more actively traded (3,607,070 versus 1,982,609). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Live Nation Entertainment, Inc. for 72 Days on average.
| DXCM | LYV | |
|---|---|---|
Market Cap | $31.86B | $39.92B |
Volume | 3,607,070 | 1,982,609 |
Sector | Health | Media |
52-Week High | $92.34 | $188.46 |
52-Week Low | $54.84 | $125.61 |
Typical Hold Time | 62 Days | 72 Days |
Enterprise Value | $31.32B | $42.13B |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Live Nation Entertainment (LYV) trades at $170.84, down 0.55% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 earnings beat with 1.05 EPS versus 0.66 expected, though Q1 and Q4 2025 missed estimates. Revenue growth continues with $25.2B in 2025, while net income margin remains thin at 0.51%. Analyst consensus is strongly bullish with 87% buy ratings and a $208.18 price target, representing 22% upside potential.
LYV benefits from strong consumer demand for live events ('funflation' trend) and record deferred revenue of $6.4B, but faces execution risks from cost pressures, legal uncertainties, and high debt levels. The stock's elevated P/E of 117.5 reflects growth expectations, making it sensitive to earnings delivery. Near-term support sits at $169 with resistance at $172.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →